Tags : Hemophilia A and B

Novo Nordisk Resumes P-III Study of Concizumab for Patients with

Shots: The company resumes the P-III program (explorer6, 7, and 8) of concizumab. The clinical trials are evaluating concizumab (SC) prophylaxis treatment in hemophilia A and B patients regardless of their inhibitor status The trials will be resumed as soon as local procedures allow. This follows pausing of the trials in Mar’20 due to the […]Read More

Novo Nordisk Halts Clinical Studies Evaluating Concizumab (anti-TFPI mAb) for

Shots: Novo Nordisk has paused its two P-III clinical studies (explorer7 and 8) and one P-II clinical study (explorer5) investigating concizumab prophylaxis treatment in hemophilia A and B patients regardless of inhibitor status The studies have been paused due to the occurrence of non-fatal thrombotic events in three patients enrolled in the ongoing P-III program. […]Read More